Polaris Group
Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for the treatment of various cancer indications, as well as provides healthcare consulting, staffing, and MDS solutions. The company was incorporated in 20… Read more
Polaris Group (6550) - Total Liabilities
Latest total liabilities as of September 2025: NT$3.99 Billion TWD
Based on the latest financial reports, Polaris Group (6550) has total liabilities worth NT$3.99 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Polaris Group - Total Liabilities Trend (2016–2024)
This chart illustrates how Polaris Group's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Polaris Group Competitors by Total Liabilities
The table below lists competitors of Polaris Group ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LX Holdings Corp. Pfd.
KO:38380K
|
Korea | ₩43.06 Billion |
|
Shenzhen KTC Technology Co. Ltd.
SHE:001308
|
China | CN¥8.55 Billion |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
China | CN¥250.93 Million |
|
Nanjing Julong Science & Technology Co Ltd Class A
SHE:300644
|
China | CN¥1.50 Billion |
|
Netlist Inc
OTCQB:NLST
|
USA | $69.64 Million |
|
Bank of Kaohsiung Ltd
TW:2836
|
Taiwan | NT$333.40 Billion |
|
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
USA | $16.49 Million |
|
Hangzhou Shenhao Technology Co Ltd
SHE:300853
|
China | CN¥1.00 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Polaris Group's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Polaris Group's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Polaris Group (2016–2024)
The table below shows the annual total liabilities of Polaris Group from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$2.32 Billion | +58.37% |
| 2023-12-31 | NT$1.46 Billion | +168.68% |
| 2022-12-31 | NT$545.18 Million | -10.36% |
| 2021-12-31 | NT$608.23 Million | +26.49% |
| 2020-12-31 | NT$480.85 Million | -3.17% |
| 2019-12-31 | NT$496.61 Million | -62.81% |
| 2018-12-31 | NT$1.34 Billion | +9.33% |
| 2017-12-31 | NT$1.22 Billion | -29.27% |
| 2016-12-31 | NT$1.73 Billion | -- |